Member Info for Azurite

Superb announcement. http://www.lse.co.uk/share-regulatory-news.asp?shareprice=ABDP&ArticleCode=ztijx644&ArticleHeadline=Significant_Contract_for_Driving_Robots

Davey, have you yet revised your target for the year?

https://www.google.co.uk/search?q=LON:HCM&stick=H4sIAAAAAAAAAONgecRoyi3w8sc9YSmdSWtOXmNU4-IKzsgvd80rySypFJLgYoOy-KR4uLj0c_UNkrMrjc3LeQAXCQZZOgAAAA&sa=X&ve

Around 20,000 shares bought by directors in the last week!

A secondary listing on the US Nasdaq exchange has helped raise Chi-Med’s profile, and has given an extra dose of momentum to the London-listed shares as well. Analysts expect this to continue, particularly as the group initiates more late-stage trials for drugs under development. Buy.

Simon To bought around 20,000 shares last month. If he's happy to buy more then I'm even happier to be invested and look forward to events unfolding over the next few years or so.

Tipped by Simon Thompson in IC too.

No meat on the bones in RNS today. Nothing really to chew on.

miti, I got in about the same time as you although I'd bought a small holding at around 1900. Davey, I wonder if the price is climbing because Christian Hogg has recently talked about HCM becoming a multi billion dollar company. Also wonder how much actually is multi in his view.

Like daveycaferacer I'm here long term.

http://www.lse.co.uk/DirectorsDeals.asp?shareprice=HCM&share=hutchison_china

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that the China Food and Drug Administration ("CFDA") has acknowledged acceptance of the New Drug Application ("NDA") for fruquintinib for the treatment of patients with advanced colorectal cancer, which triggers a milestone payment of RMB30.8 million (US$4.5 million) from Lilly to Chi-Med. The NDA is supported by data from the successful FRESCO study, a Phase III pivotal registration trial of fruquintinib in 416 patients with locally advanced or metastatic colorectal cancer ("CRC") in China, which was highlighted in an oral presentation at the American Society of Clinical Oncology Annual Meeting on June 5, 2017.

Analysts at Panmure Gordon Reconfirmed their Past ‘Buy’ rating on Shares Hutchison China Meditech Ltd (LON:HCM), Set a GBX 3530.00 Target Price per Share May 19, 2017 - By Hazel Jackson Hutchison China Meditech Ltd (LON:HCM) Rating Reaffirmed Panmure Gordon now has a GBX 3530.00 target price per share on the 1.89 billion GBP market cap company or 13.23 % upside potential. In an analyst report sent to investors and clients on Thursday morning, Hutchison China Meditech Ltd (LON:HCM) shares have had their Buy Rating reiterated by investment analysts at Panmure Gordon.

Hutchison China MediTech Ltd – (NASDAQ:HCM) received a $30.00 price target from research analysts at Canaccord Genuity in a research note issued on Thursday. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity’s price objective would indicate a potential upside of 52.28% from the stock’s current price.

Rated a BUY this week in Investors Chronicle. Listed as number 2 in their top 100 AIM listed companies.

The UK and USA presentations from last week are now on http://www.chi-med.com/investors/event-information/

I would if I could, but unable to do so this time. I am sure Dave who likes to race cafes/mini1000 will keep the rest of us updated. :)

London: Tuesday, March 21, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that it will host Research & Development ("R&D") briefings in London and New York to provide an overview of the Company's clinical pipeline of eight novel drug candidates. The events for analysts and investors will take place in London on Wednesday, March 29, and in New York on Thursday, March 30, 2017. The briefing on Wednesday, March 29, 2017 in London will begin with a keynote presentation from Dr Susan Galbraith, Vice President of Oncology Innovative Medicines and Early Development at AstraZeneca. Mr Christian Hogg, Chief Executive Officer; Dr Weiguo Su, Executive Vice President and Chief Scientific Officer; Dr Zhenping Wu, Senior Vice President of Pharmaceutical Sciences; and Dr May Wang, Senior Vice President of Business Development & Strategic Alliances, will be presenting on Chi-Med's research & development and partnering activities. Chi-Med currently has partnerships with AstraZeneca, Eli Lilly and Company and Nestlé Health Science S.A. To register for the London briefing, please contact Dr Marine Perrier by telephone at +44 20 7282 1068 or by email at marine.perrier@citigatedr.co.uk. To register for the New York briefing, please contact Matt Beck by telephone at +1 646 378 2933 or by email at mbeck@troutgroup.com.

Taken from seekingalpha.com Summary Shares are up over 50% since my last writeup on the company. Major milestone achieved with positive pivotal data for fruquintinib in third-line colorectal cancer. Four ongoing pivotal trials and four to be initiated this year. Four early stage studies to report data later this year, providing potential near term upside. Risks include disappointing data and a slowdown of China's economy, while near term dilution appears off the table. Shares of Hutchison China Meditech (NASDAQ:HCM), also known as Chi-Med, have risen over 50% since my writeup in September last year. HCM Chart HCM data by YCharts In the prior article I explained why this company is a unique biotech core buy offering both a deep clinical pipeline and China exposure for investors' portfolios. Between a sales team of over 3,200 employees and 1,900 medical professionals in charge of the company's prescription drug business, eight clinical candidates being pushed forward by a 290 person research and development team, and a validating partnership with pharma giant AstraZeneca as its exclusive first tier distributor in China, it was my opinion that the market was offering investors a bargain that would not last long. While it's true that many Chinese companies trade at discounts to their American or European peers due higher instances of fraud and other concerns, I felt in this case that the "China discount" was overdone. My focus now is on how the thesis has changed and what investors should do at this point, as well as readers who are potentially interested in the story. At a market capitalization of around $2.4 billion, the company reported $173.7 million of cash as of December 31st. Revenue for the full year grew 21% to $216.1 million, while net income grew 46% to $11.7 million. Research and development expenses increased a decent bit from $55.8 million in 2015 to $76.1 million in 2016. Ten times revenue might appear very expensive for a commercial entity, but we must keep in mind this is a clinical stage biotech with several promising late stage assets that happens to also have a prescription drug business. If and when some of these assets reach approval, it is my opinion that the stock will look cheap in retrospect.

I sold 10% a couple of days ago, happily at the time.